Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer

A Two-Arm Open Label Phase II Study of AFP464 (Aminoflavone Prodrug) in Previously-treated ER-positive or Triple-negative Breast Cancer Patients

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01015521

Enrollment

Registered

2009-11-18

Start date

2010-04-30

Completion date

Unknown

Last updated

2010-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasm

Keywords

breast cancer

Brief summary

This is a phase II study to assess the efficacy of Aminoflavone prodrug in triple negative and ER+ breast cancer.

Interventions

DRUGAminoflavone Prodrug

Aminoflavone Prodrug administered D1, D8 of 21-day cycle

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* ER+ or TN Breast Cancer * Progression on an aromatase inhibitor if ER+ * Prior treatment with taxane if TN * 18 years or older * Adequate organ function * Measurable lesion

Exclusion criteria

* symptomatic pulmonary disease * brain metastases * pregnant females

Design outcomes

Primary

Measure	Time frame
Clinical Benefit Response	6 months

Secondary

Measure	Time frame
Progression Free Survival	6 monhts

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026